- Home
- TALKW vs BMRN Comparison
TALKW vs BMRN Comparison
Compare TALKW & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TALKW | BMRN |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | 521 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 10.0B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | TALKW | BMRN |
|---|---|---|
| Price | $0.03 | $59.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $89.74 |
| AVG Volume (30 Days) | 64.2K | ★ 3.1M |
| Earning Date | 02-20-2025 | 10-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.53 |
| EPS | N/A | ★ 2.68 |
| Revenue | $181,291,000.00 | ★ $3,094,001,000.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $9.06 |
| P/E Ratio | ★ N/A | $22.36 |
| Revenue Growth | ★ 31.50 | 12.39 |
| 52 Week Low | $0.20 | $50.76 |
| 52 Week High | $0.24 | $73.51 |
Technical Indicators
Market Signals| Indicator | TALKW | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 35.07 | 63.83 |
| Support Level | $0.03 | $51.50 |
| Resistance Level | $0.04 | $61.79 |
| Average True Range (ATR) | 0.01 | 1.97 |
| MACD | -0.00 | 0.84 |
| Stochastic Oscillator | 11.45 | 69.36 |
Price Performance
Historical ComparisonAbout TALKW Talkspace Inc. Warrant
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.